Shardul Amarchand Mangaldas & Co. (SAM) and Cyril Amarchand Mangaldas (CAM) advised on Eris Lifesciences Limited’s (ELL) acquisition of remaining 30% stake in Swiss Parenterals Limited (SPL).
Shardul Amarchand Mangaldas & Co. (SAM) acted as the legal advisor to ELL in connection with its proposed acquisition of 30% of the total share capital of SPL (in which ELL currently holds 70% of the share capital) from Mr. Naishadh Shah (Director, SPL), for an aggregate consideration of INR 423.30 crores. The consideration will be discharged by ELL by way of issuance of equity shares of ELL to Mr. Naishadh Shah, on a preferential basis.
Upon completion of the proposed acquisition, subject to receipt of necessary stock exchange approvals, SPL will become a wholly owned subsidiary of ELL.
The SAM transaction team was led by Partner Nivedita Tiwari along with Partner Devesh Pandey, Principal Associate Kuhuk Jain, Associate Anushka Ganguli and Associate Sourav Paul.
Gouri Puri, Partner, Rahul Yadav, Partner and Nimish Malpani, Principal Associate advised ELL on the tax related aspects pertaining to the transaction.
Cyril Amarchand Mangaldas (CAM) acted as the legal counsel to SPL and Mr. Naishadh Shah (Seller) in connection with the proposed sale of 30% stake of SPL (in which ELL currently holds 70% of the share capital) to ELL for an aggregate consideration of INR 423,30,00,000 which will be discharged by ELL by way of issuance and allotment of equity shares to Seller by way of a preferential issue.
The Transaction Team included Ravi Shah, Arushi Bindal and Aesha Shah.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
